ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG COBAS® SARS-COV-2 & INFLUENZA A/B; COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES
|
Back to Search Results |
|
Catalog Number 09211101190 |
Device Problems
Incorrect, Inadequate or Imprecise Result or Readings (1535); Output Problem (3005); Non Reproducible Results (4029)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 05/04/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
The customer is using treidila swab for sample collection which is off-label.Note that as per the instructions for use, inadequate or inappropriate sample collection, storage, and transport may yield incorrect or invalid test results.It is also possible that the discrepancy might have occurred due to the differences in sensitivity and detection technologies between the competitor assays and the cobas liat.Within the data provided by the customer, only the 2 runs for patient 1 could be identified.Review of the dataset identified that the internal control (ic) of both runs is within range and does not show any signs of a systematic issue, with that being said the ic for one of the run is slightly delayed which might indicate a slight inhibition that may have arisen from the sample quality due to the off-label collection the customer is using.Additionally, in the curves of the runs, a slight but not strong enough amplification can be observed for the flu a target which may indicate that the samples have a low viral concentration that is below the test's limit of detection (lod).Upon a holistic review of the dataset provided for 3 different cobas analyzer provided by the custoemr (s/n (b)(4), the background and baseline levels are stable and do not show any signs of an issue.(b)(4).
|
|
Event Description
|
In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.A customer from australia alleged a discrepant results for three patients while using the cobas® sars-cov-2 & influenza a/b nucleic acid test on the cobas® liat® system.The alleged samples initially generated negative results for influenza a when tested on the cobas® liat® system (negative for sars-cov-2 and influenza b).One of the patient samples was retested on the liat, which further generated a negative result for influenza a(negative for sars-cov-2 and influenza b).The same samples were retested on two different platforms (genexpert and ausdx) which yielded a positive influenza a result for all three samples.No harm was alleged.An investigation was conducted to evaluate the customer issue.Per fda¿s eua guidance, 3 mdrs will be filed.
|
|
Search Alerts/Recalls
|
|
|